MedTrust Online and Avantra Biosciences have entered into a collaboration to involve clinicians in the earliest stages of molecular diagnostic assay development for Avantra Biosciences' QPDx multiplex immunoassay system.
The two companies will provide a global community of over 10,000 cancer care professionals with early access to the latest panels of protein biomarkers implicated in different cancers.
The system provides quantitative protein biomarker results for 10 analytes in less than an hour, requiring only five minutes for sample preparation.
The first of several multiplex assays to be evaluated include an upcoming panel developed in the recently announced collaboration between Avantra and TGen Drug Development.
Avantra intends to develop additional panels that may target ovarian, pancreatic, lung, prostate, breast, and colorectal cancers to uncover associations between protein marker levels and patient drug responses that can positively impact clinical decisions.
MedTrust CEO Christopher Yoo said this partnership will provide cancer doctors with powerful biomarker assays that can be validated with clinical insights about their utility at the point of care.
"The result of this joint effort will be better decisions based on the most accurate molecular knowledge available about an individual patient’s disease. We believe Avantra’s technology will bring a higher level of accuracy than what’s currently available and MedTrust is delighted to work with Avantra on this important advancement in cancer care," Yoo said.